Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: A systematic review

Tumori

Volumn 96, Issue 3, 2010, Pages 392-399

  Cirocchi, Roberto ^a   Farinella, Eriberto ^a   La Mura, Francesco ^a   Cavaliere, Davide ^b   Avenia, Nicola ^a   Verdecchia, Giorgio Maria ^b   Giustozzi, Gianmario ^a   Noya, Giuseppe ^a   Sciannameo, Francesco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Hospital Forlì   (Italy)

Author keywords

Advanced gastrointestinal stromal tumors; Imatinib mesylate; Surgery

Indexed keywords

IMATINIB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; METASTASIS; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SMALL INTESTINE TUMOR; STOMACH TUMOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 77954982392     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600303     Document Type: Review

References (36)

1. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA: Prognostic value of KITmutation type,mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol, 20: 3898-3905, 2002.
2. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA: PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 299: 708-710, 2003.
3. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patientwith ametastatic gastrointestinal stromal tumor. N Engl JMed, 344: 1052-1056, 2001.
4. Duffaud F, Blay JY: Gastrointestinal stromal tumours: biology and treatment. Oncology, 65: 187-197, 2003.
5. Verweij J, Van Oosterom A, Blay JY, Judson I, Rodenhuis S, Van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, Di Paola ED, Brown M, Nielsen OS: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results froman EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer, 39: 2006-2011, 2003.
6. Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinibmesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347: 472-480, 2002.
7. Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, Fuzesi L: Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol, 14: 526-532, 2007.
8. Ruka W, Rutkowski P, Szawlowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, Dziewirski W, Siedlecki JA, Michej W: Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol, 35: 87-91, 2009.
9. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, Raymond AK, Cormier JN, Pisters PWT, Pollock RE, Feig BW: Is there a role for surgery in patients with "unresectable" cKIT + gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg, 186: 665-669, 2003.
10. Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, Kim KH, Yook JH, Kim BS, Kang YK: Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol, 98: 27-33, 2008.
11. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter N, Dei Tos AP, Emile J-F, Gronchi A, Hogendoorn PCW, Joensuu H, Le Cesne A, MacClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD; GIST consensus meeting panelists: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21March 2004, under the auspices of ESMO. Ann Oncol, 16: 566-578, 2005.
12. Higgins JPT, Green S (editors): Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0 [updated February 2008]. The Cochrane Collaboration 2008. Available from www.cochrane-handbook.org.
13. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2008.
14. Greenland S, Robins J: Estimation of a common effect parameter from sparse follow-up data. Biometrics, 41: 55-68, 1985.
15. Mantel N, Haenszel W. Statistical aspects of the analysis of data fromretrospective studies of disease. J Natl Cancer Inst, 22: 719-748, 1959.
16. Choi H: Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep, 7: 307-311, 2005.
17. Andtbacka RHI, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol, 14: 14-24, 2007.
18. Bonvalot S, Eldweny H, Le Péchoux C, Vanel D, Terrier P, Cavalcanti A, Robert C, Lassau N, Le Cesne A: Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Sur Oncol, 13: 1596-1603, 2006.
19. Gold JS, van der Zwan SM, Gönen M, Maki RG, Singer S, Brennan MF, Antonescu CR, De Matteo RP: Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol, 14: 134-142, 2007.
20. Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S, Casali PG: Surgery of residual disease following molecular targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg, 245: 341-346, 2007.
21. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol, 24: 2325-2331, 2006.
22. Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, Krawczyk M, Ruka W: Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol, 93: 304-311, 2006.
23. Al-Batran SE, Hartmann JT, Heidel F, Stoehlmacher J, Wardelmann E, Dechow C, Düx M, Izbicki JR, Kraus T, Fischer T, Jäger E: Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer, 10: 145-152, 2007.
24. An YJ, Choi MG, Noh JH, Sohn TS, Kang WK, Park CK, Kim S: Gastric GIST: A single institutional retrospective experience with surgical treatment for primary disease. Eur J Surg Oncol, 33: 1030-1035, 2007.
25. Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G, Niebel W, Erhard J, Ebeling P, Zeth M, Taeger G, Seeber S, Flasshove M, Schutte J: Resection of residual disease in patients withmetastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer, 117: 316-325, 2005.
26. Hasegawa J, Kanda T, Hirota S, Fukuda M, Nishitani A, Takahashi T, Kurosaki I, Tsutsui S, Hatakeyama K, Nishida T: Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol, 12: 212-217, 2007.
27. Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC: Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery, 134: 656-666, 2003.
28. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg, 231: 51-58, 2000.
29. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, Swallow CJ: Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol, 8: 50-59, 2001.
30. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, OttMJ: The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg, 136: 383-389, 2001.
31. Judson I, Demetri G: Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol, 18:20-24, 2007.
32. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, Von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Comprehensive Cancer Network, 5 (Suppl 2): S1-29, 2007.
33. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group: Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 19 (Suppl 2): 35-38, 2008.
34. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M,Webb A, Sciot R, Van GlabbekeM, Silberman S, Nielsen OS, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet, 358: 1421-1423, 2001.
35. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet, 364: 1127-1134, 2004.
36. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinibmesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 373: 1097-1104, 2009.